Subtopic Deep Dive
Immunotherapy in Neuro-Oncology
Research Guide
What is Immunotherapy in Neuro-Oncology?
Immunotherapy in neuro-oncology applies immune checkpoint inhibitors, CAR-T cells, and tumor vaccines to modulate the glioma microenvironment and overcome myeloid suppression in brain tumors.
This subtopic focuses on checkpoint inhibitors like nivolumab and neoadjuvant anti-PD-1 therapies for recurrent glioblastoma (Cloughesy et al., 2019; Reardon et al., 2020). CAR-T cells and peptide vaccines target glioma antigens such as EGFRvIII (Sampson et al., 2010). Over 10 key papers since 2007 address immune evasion, with 1331-1953 citations each.
Why It Matters
Neoadjuvant anti-PD-1 therapy induces intratumoral T-cell responses and extends survival in recurrent glioblastoma patients (Cloughesy et al., 2019, 1331 citations). Nivolumab fails to outperform bevacizumab in recurrent cases, highlighting blood-brain barrier and immunosuppressive challenges (Reardon et al., 2020, 1349 citations). These advances inform EANO guidelines for integrating immunotherapy into glioma protocols (Weller et al., 2020, 1728 citations; Lim et al., 2018, 1348 citations), potentially improving outcomes in immunotherapy-resistant gliomas.
Key Research Challenges
Myeloid Cell Suppression
Microglia and macrophages create an immunosuppressive tumor microenvironment that hinders T-cell infiltration in gliomas (Hambardzumyan et al., 2015, 1574 citations). This myeloid suppression resists checkpoint blockade. Therapeutic strategies must reprogram these cells for effective immunotherapy.
Blood-Brain Barrier Penetration
Immune cells and therapeutics face limited access to brain tumors despite systemic administration (Tan et al., 2020, 1953 citations). Nivolumab shows no survival benefit over bevacizumab in recurrent glioblastoma due to this barrier (Reardon et al., 2020, 1349 citations). Neoadjuvant approaches partially overcome it by priming responses (Cloughesy et al., 2019).
Antigen Escape Mechanisms
Gliomas evade vaccines through EGFRvIII loss after prolonged progression-free survival (Sampson et al., 2010, 791 citations). Cancer stem cells like CD133+ populations contribute to immune resistance (Liu et al., 2006, 1769 citations). Combination therapies are needed to target heterogeneous antigens.
Essential Papers
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari, Tim R. Fenton, Robert Bachoo et al. · 2007 · Genes & Development · 2.3K citations
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion t...
Management of glioblastoma: State of the art and future directions
Aaron C. Tan, David M. Ashley, Giselle Y. López et al. · 2020 · CA A Cancer Journal for Clinicians · 2.0K citations
Abstract Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predo...
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Gentao Liu, Xiangpeng Yuan, Zhaohui Zeng et al. · 2006 · Molecular Cancer · 1.8K citations
Abstract Background Recently, a small population of cancer stem cells in adult and pediatric brain tumors has been identified. Some evidence has suggested that CD133 is a marker for a subset of leu...
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller, Martin J. van den Bent, Matthias Preusser et al. · 2020 · Nature Reviews Clinical Oncology · 1.7K citations
Abstract In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized...
Cancer stem cells in glioblastoma
Justin D. Lathia, Stephen C. Mack, Erin E. Mulkearns-Hubert et al. · 2015 · Genes & Development · 1.6K citations
Tissues with defined cellular hierarchies in development and homeostasis give rise to tumors with cellular hierarchies, suggesting that tumors recapitulate specific tissues and mimic their origins....
The role of microglia and macrophages in glioma maintenance and progression
Dolores Hambardzumyan, David H. Gutmann, Helmut Kettenmann · 2015 · Nature Neuroscience · 1.6K citations
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
David A. Reardon, Alba A. Brandes, Antonio Omuro et al. · 2020 · JAMA Oncology · 1.3K citations
ClinicalTrials.gov Identifier: NCT02017717.
Reading Guide
Foundational Papers
Start with Furnari et al. (2007, 2287 citations) for glioma biology basics, then Liu et al. (2006, 1769 citations) on CD133+ stem cell resistance, and Sampson et al. (2010, 791 citations) for initial EGFRvIII vaccine data to build immunotherapy context.
Recent Advances
Study Cloughesy et al. (2019) for neoadjuvant PD-1 survival benefits, Reardon et al. (2020) for nivolumab trial failures, and Weller et al. (2020, EANO guidelines) for clinical integration.
Core Methods
Checkpoint blockade (nivolumab, PD-1); peptide vaccines (EGFRvIII); TME modulation targeting microglia/macrophages; assessed via Kaplan-Meier survival, immune profiling, and preclinical stem cell models.
How PapersFlow Helps You Research Immunotherapy in Neuro-Oncology
Discover & Search
Research Agent uses searchPapers and exaSearch to find immunotherapy trials in gliomas, then citationGraph on Cloughesy et al. (2019) reveals 500+ connected papers on PD-1 neoadjuvant effects, while findSimilarPapers identifies related CAR-T studies from Lim et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to extract immune response data from Reardon et al. (2020), verifies survival claims with verifyResponse (CoVe), and runs PythonAnalysis on GRADE-graded hazard ratios using pandas for statistical significance in nivolumab vs. bevacizumab outcomes.
Synthesize & Write
Synthesis Agent detects gaps in myeloid suppression therapies via contradiction flagging across Hambardzumyan et al. (2015) and Cloughesy et al. (2019); Writing Agent uses latexEditText, latexSyncCitations for 20-paper reviews, and latexCompile to generate formatted manuscripts with exportMermaid diagrams of TME modulation pathways.
Use Cases
"Analyze survival data from nivolumab trials in recurrent GBM using Python."
Research Agent → searchPapers('nivolumab glioblastoma') → Analysis Agent → readPaperContent(Reardon 2020) → runPythonAnalysis(pandas survival curves, matplotlib Kaplan-Meier plots) → researcher gets CSV-exported hazard ratios and p-values.
"Write a LaTeX review on neoadjuvant PD-1 in gliomas with citations."
Synthesis Agent → gap detection(Cloughesy 2019 + Weller 2020) → Writing Agent → latexEditText(intro/methods), latexSyncCitations(15 papers), latexCompile → researcher gets compiled PDF with inline citations and figures.
"Find GitHub code for CAR-T modeling in glioma TME."
Research Agent → searchPapers('CAR-T glioma') → Code Discovery → paperExtractUrls(Lim 2018) → paperFindGithubRepo → githubRepoInspect → researcher gets annotated repo with simulation scripts for immune cell dynamics.
Automated Workflows
Deep Research workflow scans 50+ papers on checkpoint inhibitors via searchPapers → citationGraph → structured report with GRADE tables on efficacy (e.g., Reardon 2020). DeepScan applies 7-step CoVe to verify immunotherapy claims in EANO guidelines (Weller 2020), outputting verified summaries. Theorizer generates hypotheses on combining CAR-T with myeloid reprogramming from Hambardzumyan 2015 and Cloughesy 2019.
Frequently Asked Questions
What defines immunotherapy in neuro-oncology?
It uses checkpoint inhibitors, CAR-T, and vaccines to target glioma immune evasion, addressing myeloid suppression and blood-brain barrier issues (Lim et al., 2018).
What are key methods in glioma immunotherapy?
Neoadjuvant anti-PD-1 promotes T-cell responses (Cloughesy et al., 2019); EGFRvIII vaccines induce immunity but face escape (Sampson et al., 2010); nivolumab tested vs. bevacizumab (Reardon et al., 2020).
What are major papers?
Cloughesy et al. (2019, Nature Medicine, 1331 citations) on neoadjuvant PD-1; Reardon et al. (2020, JAMA Oncology, 1349 citations) on nivolumab; Lim et al. (2018) reviews state (1348 citations).
What open problems exist?
Overcoming microglia suppression (Hambardzumyan et al., 2015); antigen heterogeneity in stem cells (Liu et al., 2006); poor BBB penetration limits systemic therapies (Tan et al., 2020).
Research Glioma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Immunotherapy in Neuro-Oncology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Glioma Diagnosis and Treatment Research Guide